KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Inventory (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Inventory data on record, last reported at $152.9 million in Q4 2025.

  • For Q4 2025, Inventory rose 22.02% year-over-year to $152.9 million; the TTM value through Dec 2025 reached $152.9 million, up 22.02%, while the annual FY2025 figure was $152.9 million, 22.02% up from the prior year.
  • Inventory reached $152.9 million in Q4 2025 per PCRX's latest filing, down from $157.7 million in the prior quarter.
  • Across five years, Inventory topped out at $157.7 million in Q3 2025 and bottomed at $64.6 million in Q1 2021.
  • Average Inventory over 5 years is $105.4 million, with a median of $99.6 million recorded in 2021.
  • Peak YoY movement for Inventory: surged 60.45% in 2022, then decreased 10.31% in 2023.
  • A 5-year view of Inventory shows it stood at $98.6 million in 2021, then fell by 2.52% to $96.1 million in 2022, then rose by 8.63% to $104.4 million in 2023, then increased by 20.06% to $125.3 million in 2024, then grew by 22.02% to $152.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Inventory were $152.9 million in Q4 2025, $157.7 million in Q3 2025, and $148.2 million in Q2 2025.